Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-09-23
2008-09-23
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S250000
Reexamination Certificate
active
11672177
ABSTRACT:
The present invention is directed to substituted thiatriazaacenaphthylene-6-carbonitrile compounds of formula (I):and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
REFERENCES:
Selby, Synthesis of a Novel Thiadiazacyclazine, J. Org. Chem., 53, 2386-2388 (1988).
Klijn JG, Berns PM, Schmitz PI and Foekens JA; The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients,Endocr. Rev., 1992, 13, 3-17.
Salomon D and Gullick W; The erbB family of receptors and their ligands: Multiple targets for therapy,Signal, 2001, 2, 4-11.
Eckstrand AJ, Sugawa N, James CD and Collins VP; Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails,Proc. Acad. Natl. Sci. USA, 1992, 89, 4309-4313.
Wickstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, Traweek ST, Wong AJ, Zalutsky MR and Bigner, DD; Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas,Cancer Res., 1995, 55, 3140-3148.
V. Koprivica, et al, EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans,Science, 2005, 310, 106.
Horizons in Cancer Therapeutics: From Bench to Bedside, Signal Transduction Inhibitors, 2001, 2(2), ISSN 1532-3048.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL; Human breast cancer: Correlation of relapse and survival with amplification of HER-2
eu oncogene,Science, 1987, 235, 177-82.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al; Studies of the HER-2
eu proto-oncogene in human breast and ovarian cancer,Science, 1989, 244, 707-712.
Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS and Podrantz KC; HER-2
eu expression: A major prognostic factor in endometrial cancer,Gynecol. Oncol., 1992, 47, 179-85.
Kirsch DG and Hochberg FH; Targeting HER-2 in brain metastases from breast cancer,Clin. Can. Res., 2003, 9, 5435-5436.
Grossi PM, Ochiai H, Archer GE, McLendon RE, Zalutsky MR, Friedman AH, Friedman HS, Bigner DD and Sampson JH; Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer,Clin. Can. Res., 2003, 9, 5514-5520.
Wang X, et al., Epidermal growth factor receptor is a cellular receptor for juman cytomegalovirus; Nature, Jul. 24, 2003, vol. 424, 456-461.
Yeatman TJ, A renaissance for SRC, Nature, Jun. 2004, vol. 4.
Goldenberg-Furmanov, et al., Lyn is a Target Gene for Prostate Cancer Sequence-based Induces Regression of Human Tumor Xenografts; Cancer Research, Feb. 1, 2004, 64, 1058-1064.
Shah, et al., Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor, Science, Jul. 16, 2004, vol. 305, 399-401.
Donato, et al., BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571; Blood, Jan. 15, 2003, 101(2).
Elgemeie, G. H.; Elghandour, Ahmed H.; Elzanate, A. M.; Ahmed, S. A.; Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1997), (21), 3285-3290.
Connolly Peter J.
Emanuel Stuart L.
Hayden Stuart
Johnson Sigmond G.
Lagu Bharat
Janssen Pharmaceutica N.V.
Leeser Erich A
Ren Yunling
Wilson James O.
LandOfFree
Substituted thiatriazaacenaphthylene-6-carbonitrile kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted thiatriazaacenaphthylene-6-carbonitrile kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted thiatriazaacenaphthylene-6-carbonitrile kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3940254